Shots:

• Bio-Thera to receive $165M upfront- regulatory- and commercial milestones and is eligible to receive royalties on sales of the product. BeiGene to get the right to develop- manufacture- and commercialize BAT1706 in China- including Hong Kong- Macau- and Taiwan while Bio-Thera will retain rights for the therapy outside the licensed territory
• The NMPA has recently accepted the BLA for BAT1706. The collaboration allows Bio-Thera to leverage BeiGene’s expertise to accelerate the development and commercialization of BAT1706 as a single agent regimen or as a component of combinational therapies
• BAT1706 is a mAb- a biosimilar referencing Avastin which is a treatment option for solid tumor indications in China such as colorectal- lung- and liver cancers. Additionally- Bio-Thera plans to file for the approval of BAT1706 in the US and EU in the Q4’20

­ Ref: BeiGene  Image: JHL Biotech